Pakke med 10 hetteglass6 på lagerSpar 19 %Retatrutide 50 mg
Tri-agonist GLP-1 / GIP / glukagon-forskningspeptid
Retatrutide tri-agonist research peptide, Australian-shipped. Lab-verified ≥99% purity.
Kun til forskningsbruk. Denne forbindelsen selges strengt til in vitro-forskning og laboratorieformål og er ikke beregnet for menneskelig konsum eller terapeutisk bruk. Ved kjøp bekrefter du at du er en kvalifisert forsker og godtar vår fullstendige ansvarsfraskrivelse.
Bare 6 pakker igjen
Trippelreseptoragonist-forskningspeptid studert for kombinerte virkninger på GLP-1-, GIP- og glukagonsignaleringsveier i metabolske forskningsapplikasjoner.
Retatrutide is a synthetic tri-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously. It is part of a new generation of incretin-receptor research compounds developed to study combined activation of multiple metabolic pathways. Quantum Labs supplies Retatrutide as a lyophilised powder for Australian research applications.
Retatrutide is studied alongside other incretin-receptor agonists — semaglutide (single-agonist GLP-1) and tirzepatide (dual-agonist GLP-1/GIP) — in pre-clinical and clinical research literature. The tri-agonist mechanism is the distinguishing feature that places it in its own research category. Material is HPLC-verified to ≥99% purity and ships from Australian stock; supplied for laboratory research use only.
Mekanisme
Studert for simultan agonisme av GLP-1-, GIP- og glukagonreseptorer. Forskning knyttet til markører for metabolsk rate, metthet og energiforbruk i studiepopulasjoner.
HPLC-verifisert mot en renhetsspesifikasjon på ≥99 %. Uavhengig testet av akkrediterte tredjepartslaboratorier.
Retatrutide — vanlige spørsmål
What is Retatrutide?
Retatrutide is a synthetic tri-agonist research peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors. It is a newer-generation incretin-receptor research compound.
Is Retatrutide legal in Australia?
Retatrutide is not an approved therapeutic in Australia and remains available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies Retatrutide for research use only — it is not a substitute for prescription weight-loss medication.
What is the difference between Retatrutide and Tirzepatide?
Tirzepatide is a dual-agonist activating GLP-1 and GIP receptors. Retatrutide is a tri-agonist activating GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is the distinguishing pharmacological feature of Retatrutide.
What is the difference between Retatrutide and Mounjaro?
Mounjaro is the brand name for the approved prescription medicine tirzepatide. Retatrutide is a separate research peptide with an additional glucagon-receptor agonism. They are different molecules studied in parallel research literature. Quantum Labs does not supply prescription medicines.
What is the typical Retatrutide research dosage?
Published clinical research has used Retatrutide doses across a wide titration range. Research-protocol dosing varies by model. Human therapeutic dosing is not established. Quantum Labs supplies this compound for laboratory and pre-clinical research use only. It is not represented for human therapeutic use, and questions about clinical dosing, treatment effects, or personal use should be directed to a qualified medical practitioner.
Guider relatert til Retatrutide
Forskere utforsker også
Pakke med 10 hetteglassSpar 22 %MOTS-c
Lyofilisert pulver10 mg · 2 strengths
Mitokondrielt avledet metabolsk peptid
I 2 stacker
Pakke med 10 hetteglassSpar 17 %5-Amino-1MQ
Lyofilisert pulver50 mg · 3 strengths
NNMT-hemmer, forskningsforbindelse
Pakke med 10 hetteglassSpar 15 %L-Carnitine
Sterile solution10 ml × 600 mg/ml
Mitokondriell fettsyretransporter
I 1 stack